Anthrax antitoxin monoclonal antibody approved in the United States and Canada

Elusys has been awarded over $450 million in procurement and development contracts by the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Disease (NIAID) and the Department of Defense (DoD). Working closely with these Government partners, Elusys advanced ANTHIM® to commercial approval - and now ANTHIM® is currently stockpiled by the U.S. Strategic National Stockpile to strengthen US biosecurity against a potential anthrax attack.

​

Elusys contracted with the Public Health Agency of Canada beginning in 2022 to deliver ANTHIM® to the NESS.

​

Details including Indications and Usage for Anthim and Important Safety Information can be found by visiting the website below.